Pasithea Other Operating Expenses vs Gross Profit Analysis
| KTTA Stock | USD 3.18 0.01 0.31% |
Pasithea Therapeutics financial indicator trend analysis is much more than just breaking down Pasithea Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pasithea Therapeutics is a good investment. Please check the relationship between Pasithea Therapeutics Other Operating Expenses and its Gross Profit accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Other Operating Expenses vs Gross Profit
Other Operating Expenses vs Gross Profit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pasithea Therapeutics Other Operating Expenses account and Gross Profit. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Pasithea Therapeutics' Other Operating Expenses and Gross Profit is -0.39. Overlapping area represents the amount of variation of Other Operating Expenses that can explain the historical movement of Gross Profit in the same time period over historical financial statements of Pasithea Therapeutics Corp, assuming nothing else is changed. The correlation between historical values of Pasithea Therapeutics' Other Operating Expenses and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Operating Expenses of Pasithea Therapeutics Corp are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Other Operating Expenses i.e., Pasithea Therapeutics' Other Operating Expenses and Gross Profit go up and down completely randomly.
Correlation Coefficient | -0.39 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pasithea Therapeutics. It is also known as Pasithea Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Pasithea Therapeutics Corp minus its cost of goods sold. It is profit before Pasithea Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most indicators from Pasithea Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pasithea Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At present, Pasithea Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 31 M, whereas Sales General And Administrative To Revenue is forecasted to decline to 16.32.
| 2010 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 1.4K | 32.4K | 517.7K | 543.5K | Cost Of Revenue | 17.3K | 113.2K | 648.5K | 680.9K |
Pasithea Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Pasithea Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.79) | Revenue Per Share 0.37 | Quarterly Revenue Growth 14.981 | Return On Assets (0.38) | Return On Equity (0.63) |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.